ECSP11010884A - METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE - Google Patents

METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE

Info

Publication number
ECSP11010884A
ECSP11010884A ECSP11010884A ECSP11010884A EC SP11010884 A ECSP11010884 A EC SP11010884A EC SP11010884 A ECSP11010884 A EC SP11010884A EC SP11010884 A ECSP11010884 A EC SP11010884A
Authority
EC
Ecuador
Prior art keywords
disease
identification
genetic variant
alzheimer
interest
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Allen D Roses
Original Assignee
Zinfandel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zinfandel Pharmaceuticals Inc filed Critical Zinfandel Pharmaceuticals Inc
Publication of ECSP11010884A publication Critical patent/ECSP11010884A/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Aquí se proporciona un método para la identificación de una variante genética que está asociada con el desarrollo de un padecimiento de interés (por ejemplo, la enfermedad de Alzheimer), y las variantes genéticas identificadas de esta manera. También se proporcionan métodos de tratamiento con un ingrediente activo (por ejemplo, con un agente activo particular y/o en una etapa más temprana), al momento de detectar una variante genética aquí descrita. En algunas modalidades, la variante genética es un polimorfismo de eliminación/inserción (DIP) del gen TOMM40. También se proporcionan los equipos para determinar si un sujeto se encuentra en un riesgo aumentado de desarrollar la enfermedad de Alzheimer de presentación tardía. Además se proporcionan equipos para determinar si un sujeto actúa en respuesta al tratamiento para un padecimiento de interés con un agente activo.Here a method is provided for the identification of a genetic variant that is associated with the development of a disease of interest (for example, Alzheimer's disease), and the genetic variants identified in this way. Methods of treatment with an active ingredient (for example, with a particular active agent and / or at an earlier stage) are also provided, at the time of detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion / insertion polymorphism (DIP) of the TOMM40 gene. Equipment is also provided to determine if a subject is at an increased risk of developing late-presenting Alzheimer's disease. In addition, equipment is provided to determine if a subject acts in response to treatment for a condition of interest with an active agent.

ECSP11010884 2008-08-12 2011-03-11 METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE ECSP11010884A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8820308P 2008-08-12 2008-08-12
US18667309P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
ECSP11010884A true ECSP11010884A (en) 2011-12-30

Family

ID=47827565

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP11010884 ECSP11010884A (en) 2008-08-12 2011-03-11 METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE

Country Status (1)

Country Link
EC (1) ECSP11010884A (en)

Similar Documents

Publication Publication Date Title
CO6351823A2 (en) METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE
CO6331372A2 (en) PARP INHIBITOR 4-IODO-3-NITROBENZAMIDE OR A METABOLITE OF THE SAME
MX2024004195A (en) METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM.
CO2021009163A2 (en) Amyloid precursor protein (app) arni agent compositions and method of use thereof
UY31816A (en) AGENT FOR THE TREATMENT AND / OR PREVENTION OF AN AUTOIMMUNE DISEASE AND FOR THE FORMATION OF REGULATORY CELLS
ES2571104T3 (en) Stabilization of RNA and extraction of RNA present in intact cells within a blood sample
UY34701A (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFIT
CO6640308A2 (en) Method of delivery of decision support systems (dss) and electronic health records (ehr) for reproductive care, preconceptive care, fertility treatments and other health conditions
MX2009002936A (en) BIOMARCATORS OF THE OBJECTIVE, EFFECTIVENESS, DIAGNOSIS, AND / OR FORECAST MODULATION FOR RAF INHIBITORS.
BR112013030366A2 (en) computer program method, apparatus and product
AR088827A1 (en) METHODS TO TREAT, DIAGNOSE, AND MONITOR ALZHEIMER'S DISEASE
CR9686A (en) METHOD FOR PREDICTION OF THE RESPONSE TO A TREATMENT
CY1112579T1 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SUNGLASSES
PA8800801A1 (en) APOE STATE DEMENDED IMMUNOTHERAPY REGIMES
ATE525093T1 (en) MODELS FOR VACCINE EVALUATION
CU23815A3 (en) DIARILURES FOR THE TREATMENT OF PULMONARY HYPERTENSION
CL2008001057A1 (en) Agent for the treatment of mycosis produced by saprolegnia, achlya and / or aphanomyces in fish, which comprises at least one fungicide selected from a) inhibitors of mitosis and cell division, b) inhibitors of ergosterol synthesis or, c) derivatives of pyridine, benzopiranone, carbonitrile, quinolines, among others.
MX2015012176A (en) Methods of using zscan4 for rejuvenating human cells.
WO2009152484A3 (en) Methods and platforms for drug discovery
CL2022000262A1 (en) Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor (application divisional no. 202100251)
CL2013003307A1 (en) Agent comprising ciazofamide or fenamidone; and its use to treat mycosis in fish and invertebrates in all stages of development caused by fungi of the saprolegnia, achlya and aphanomyces genera (div.sol.no 1056-08).
AR072949A1 (en) ANALYSIS OF SUBSTRATES THAT HAVE DEPOSITED AGENTS OVER THE SAME
CL2013000709A1 (en) Composition containing nifurtimox and an anthelmintic selected from: pf1022, emopdepside, tribendimidine, amidantel, bay d 9216, praziquantel or benzyl benzoate; useful in the treatment of diseases caused by giardias (div. sol. 1577-10).
DOP2012000316A (en) METHOD FOR DIAGNOSING A RESPONSE TO TREATMENT IN SUBJECTS WITH MULTIPLE SCLEROSIS
MX358594B (en) Disease risk factors and methods of use.